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Abstract
Background: Progressive multifocal leukoencephalopathy (PML), a rare devastating demyelinating disease caused by the
polyomavirus JC (JCV), occurs in severely immunocompromised patients, most of whom have advanced-stage HIV infection.
Despite combination antiretroviral therapy (cART), 50% of patients die within 6 months of PML onset. We conducted a
multicenter, open-label pilot trial evaluating the survival benefit of a five-drug cART designed to accelerate HIV replication
decay and JCV-specific immune recovery.
Methods and Findings: All the patients received an optimized cART with three or more drugs for 12 months, plus the fusion
inhibitor enfuvirtide during the first 6 months. The main endpoint was the one-year survival rate. A total of 28 patients were
enrolled. At entry, median CD4+ T-cell count was 53 per microliter and 86% of patients had detectable plasma HIV RNA and
CSF JCV DNA levels. Seven patients died, all before month 4. The one-year survival estimate was 0.75 (95% confidence
interval, 0.61 to 0.93). At month 6, JCV DNA was undetectable in the CSF of 81% of survivors. At month 12, 81% of patients
had undetectable plasma HIV RNA, and the median CD4+ T-cell increment was 105 per microliter. In univariate analysis,
higher total and naive CD4+ T-cell counts and lower CSF JCV DNA level at baseline were associated with better survival. JCV-
specific functional memory CD4+ T-cell responses, based on a proliferation assay, were detected in 4% of patients at
baseline and 43% at M12 (P=0.008).
Conclusions: The early use of five-drug cART after PML diagnosis appears to improve survival. This is associated with
recovery of anti-JCV T-cell responses and JCV clearance from CSF. A low CD4+ T-cell count (particularly naive subset) and
high JCV DNA copies in CSF at PML diagnosis appear to be risk factors for death.
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Introduction
Human polyomavirus JC (JCV) is the causative agent of
progressive multifocal leukoencephalopathy (PML), a rare demy-
elinating disease of the central nervous system (CNS) involving
lytic infection of oligodendrocytes. PML occurs in severely
immunocompromised individuals. The incidence of PML in-
creased sharply during the HIV/AIDS pandemic, up until 1996
[1] and the advent of combination antiretroviral therapy (cART)
era [2,3]. It declined thereafter, but less slowly than the relative
frequency of other AIDS-defining events [4]. Moreover, during
the period 2001–2003, compared to the pre-cART era, the
smallest decline in mortality observed in the French Hospital
Database on HIV concerned patients with PML [4]. Recent
results of the ART Cohort Collaboration confirm that PML, along
with non-Hodgkin’s lymphoma, remains associated with a higher
risk of death than other AIDS-defining events [5].
T-cell responses likely play a key role in controlling intracerebral
JCV replication. Indeed, specific cytotoxic CD8+ T-lymphocyte
responses to JCV were found to be undetectable in patients who
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20967subsequently died, in contrast to survivors [6]. Help from CD4+
T-lymphocytes is required for optimal memory CD8+ T-cell
responses during chronic viral infections [7]. We have previously
reported the critical role of JCV-specific CD4+ T-cell responses in
the control of JCV infection, and the lack of such responses in the
early stages of active PML [8].
T od a t e ,n os p e c i f i ca n t i - J C Vt r e a t m e n th a ss h o w ns i g n i f i c a n t
clinical efficacy in patients with PML [9]. Triple-drug ART has
significantly improved the prognosis of HIV-associated PML [10–
1 2 ] ,l i k e l yi n d i r e c t l yb yr e s t o r i n gC D 4 + T-cell responses to JCV [8].
However, about 50% of cART-treated patients still die within 6
months after PML clinical onset [9,12,13], while the remainders
survive for more than a year [9,14,15]. In addition, most survivors
have severe functional sequelae [9,12,15]. We wondered whether the
early use of a more patent ART based on five-drug combination after
PML onset could improve survival and neurological outcome, by
accelerating the decay of HIV replication and, thus, JCV-specific
T-cell restoration. The fusion inhibitor enfuvirtide, a 36-amino-acid
peptide mimicking the HR2 region of HIV-1 gp41, prevents the
completion of the HIV fusion sequence, thereby blocking cell entry.
Enfuvirtide has been shown to bolster the potency of antiretroviral
combinations in both naive and treatment-experienced HIV-infected
patients [16–18].
We conducted a prospective multicenter study evaluating the
effect of five-drug antiretroviral treatment including enfuvirtide on
PML outcome.
Methods and Patients
The protocol for this trial and supporting CONSORT checklist
are available as supporting information (see Protocol S1 and
Checklist S1).
Study Design
The ANRS 125 trial, sponsored by the French National Agency
for Research on AIDS and Viral Hepatitis (ANRS), was a
multicenter open-label non comparative pilot study designed to
assess the effect of an early use of five-drug cART including
enfuvirtide on survival one year after PML diagnosis in HIV-1-
infected patients. The study was designed to show an expected
one-year survival rate of 70%, significantly higher than 45% which
was the average of the one-year survival rate observed in previous
reports [11–13,15,19]. A sample size of 24 subjects was chosen
with the one-step Fleming test, with a power of 80% and a type-1
error of 5%. To compensate for invalid inclusions (up to 25%), it
was decided to enroll 30 patients. The Institutional Review Board
of Bicetre Hospital approved the study protocol and all clinical
investigations conformed to the International Conference on
Harmonization, Good Clinical Practice, and the Declaration of
Helsinki. The Clinical.Trials.gov identifier is NCT00120367.
Patients
All subjects had documented HIV type 1 (HIV-1) infection. All
subjects were required to have a diagnosis of active PML, with less
than 90 days of clinical progression [20], documented less than 30
days before study entry. Inclusion criteria were as follows: i)
neurological findings compatible with focal lesions of the CNS; ii)
one or more focal white-matter abnormalities, with no mass effect
or enhancement, on cerebral magnetic resonance imaging (MRI),
3) no other likely cause; iv) detection of JCV DNA in CSF by
polymerase chain reaction (PCR) or histopathological evidence of
PML on brain biopsy. Written informed consent was obtained
from each study participant or from next of kin if decision-making
capacity was impaired. The exclusion criteria included age less
than 18 years; pregnancy or breast-feeding; HIV-2 coinfection;
concomitant opportunistic CNS infection; prior or concomitant
immunotherapy (interleukin 2, alpha-interferon.); prior or con-
comitant treatment with cidofovir; prior treatment with enfuvir-
tide; and contraindications to enfuvirtide therapy. An independent
committee validated all the diagnoses of PML.
Study Treatments
All the participants received an effective cART for 12 months,
plus enfuvirtide for the first 6 months. The choice of regimen was
based on the individual ART history. Patients, who had never
received ART when PML was diagnosed, received efavirenz,
ritonavir-boosted lopinavir, and the fixed-dose emtricitabine-
tenofovir combination. ART-experienced patients received drugs
belonging to at least two different antiretroviral families, chosen on
the basis of their treatment history and viral resistance genotyping
results. Beyond 6 months, only patients with limited therapeutic
options were maintained on enfurvirtide.
Follow-up
Each participant was followed for one year. As the mean interval
between the enrolment visit and the outset of enfuvirtide therapy was
1 . 4d a y s( r a n g e0t o1 1d a y s ) ,t h ed a t eo ft h ef i r s td o s eo fe n f u v i r t i d e
was chosen as the study baseline. The patients had physical
examinations, including a standardized neurological examination
and Karnosky performance-status measurement, at baseline, week 6
(W6),month3(M3)andmonth6(M6).Karnoskyperformance-status
and the modified Rankinscale (MRS) [21] were assessed at month 12
(M12). Cerebral MRI was performed at baseline and between W6
and M6, in case of clinical progression. Blood samples for HIV RNA
assay, lymphocyte phenotyping and assessment of JCV-specific T-cell
responses were collected at baseline, W6, M3, M6 and M12. Lumbar
puncture for HIV RNA and JCV DNA assay in CSF was performed
at baseline, M3 and M6.
Neurological scores. We used a standardized neurological
examination from the NIH Stroke Scale [22], adapted for PML
(Table S1). Briefly, this scale includes an assessment of consciousness,
motor and sensory functions, coordination, cranial nerve functions,
phonation, swallowing, visual fields, and cognition (language, memory
and executive functions). A summary score ranging from 0 (normal) to
60 (very abnormal) was determined for each examination.
Laboratory Methods. JCV DNA was quantified in CSF by
using a quantitative real-time PCR method, [23]. Briefly, DNA
was extracted from 200 microliter of CSF with the QIAamp DNA
blood kit (QIAGEN GmbH, Hilden, Germany), according to the
manufacturer’s protocol. A 113-bp fragment of the open reading
frame coding for the large T antigen was amplified with the JCV
primers PEP3 (59 gga aag tct tta ggg tct tct acc ttt 39) and PEP6 (59
gaa gac cgt ttt tgc cat gaa ga 39). PCR product was detected with
the HuPo1 probe (59 atc acg ggc aaa cat 39). To control for the
presence of PCR inhibitors, an internal DNA control (DICO
Ampli r-gene; Argene, Varilhes, France) was simultaneously
amplified in each PCR run. The detection limit was 100 copies
per milliliter.
Flow cytometry used a FACsCalibur device (Becton Dickinson,
Rungis, France), with monoclonal antibodies and reagents provided by
the same manufacturer. T-cells subsets are defined by the following
antibody expression patterns: Naive subset, CD45RA+CD62L+;
Central memory subset, CD45RA2CD62L+; Effector memory
subset, CD45RA2CD62L2; Effector subset, CD45RA+CD62L2.
JCV-specific CD4+ T-cell responses were assessed in proliferation
assays with purified JCV (MAD-4 strain) [8]. In each experiment a
proliferation index (PI) was determined as the ratio of median counts
per minute (cpm) of activated wells (in quadriplicate) to unstimulated
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considered significant if the following conditions were met: (i) median
PI.3, (ii) median cpm of activated wells .2500, and (iii) no
significant proliferation of CD4 T-cell-depleted PBMC in response to
JCV. Positive control wells contained phytohemagglutinin (PHA) or
Staphylococcal Enterotoxin B (SEB).
To investigate anti-JCV effector T-cell responses, we used an ex
vivo interferon-gamma Elispot assay with PBMC and 14 pools of
overlapping 15-amino-acid peptides covering the entire JCV VP-1
protein. In some patients, the effect of JCV peptide pools on T-cell
responses was also examine by flow cytometry, the interferon-
gamma responses mainly involved CD8 T-cells. The pools were
used at 2 mg per milliliter. Positive controls used PMA (50 ng per
milliliter) and ionomycin (500 ng per milliliter). The response to
each pool was considered positive if the mean number of spot-
forming cells (SFC) per 10
6 PBMC in activated wells (in triplicate)
was more than 2-fold that of untreated wells (background) and also
higher than the background plus 100 SFC. A patient was
considered to be a responder, i.e. to have a detectable anti-JCV
effector T-cell response, if he or she had a positive response to at
least one peptide pool.
Statistical considerations. The primary endpoint was the
one-year survival rate. Secondary endpoints were the percentage
of patients who survived at M12 with a MRS score below 3 (slight
disability, independent for activities of daily-living); the percentage
change in neurological scores between baseline and M6; the
change in Karnofsky performance-status between baseline and
M12; the change in CSF JCV level and the proportion of patients
with CSF JCV clearance at M6; and the changes in CD4+ and
CD8+ T-cell subsets and in JCV-specific T-cell responses between
baseline and W6, M3, M6 and M12. Non-parametric methods
(Wilcoxon’s signed-rank test, Mann-Whitney test, Fisher’s two-
sided exact test, and McNemar’s test) were used to compare
continuous and categorical variables. Survival rates were estimated
with the Kaplan-Meier method from the first dose of enfuvirtide.
Survival curves were compared with the log-rank test.
Results
Between April 2005 and December 2006, 29 patients were
enrolled in six centers, including 21 patients in the main center
(Bice ˆtre Hospital, Paris area). One patient subsequently withdrew
consent, and the study population therefore consisted of 28
patients.
Characteristics at entry
Baseline clinical and immunovirological data are shown in
Table 1. The median interval between neurological symptom
onset and study entry was 46 days (range, 11 to 88). The 12
patients who had never received antiretroviral drugs did not differ
significantly from the 16 previously treated patients, with the
exception of a lower plasma HIV RNA value in the latter (Mann-
Whitney test, P=0.017). At inclusion, all four patients with plasma
HIV RNA below 40 copies/mL had positive JCV PCR in CSF.
These patients had started an ARV treatment for less than 2
months before inclusion.
All the patients received enfuvirtide until death or for at least 6
months. Five patients continued to receive enfuvirtide after 6
Table 1. Characteristics of patients at enrolment, according to outcome.
Variables Total (n=28) Alive (n=21) Deceased (n=7) P-values
ART naive (#) 12 8 4 0.42
Prior AIDS (#) 9 8 1 0.37
Gender (men: women) 22: 6 15: 6 7: 0 0.29
Age (years) 42 (35–48) 42 (36–49) 42 (35–46) 0.71
Time before study entry (days) 46 (32–69) 46 (35–71) 31 (21–59) 0.22
Neurological Score 7.0 (5.0–10.8) 7.0 (5.0–10.5) 7.0 (3.0–15.0) 0.89
Karnofsky Performance-Status (%) 60 (40–70) 50 (40–70) 60 ‘40–70) 0.75
Total CD4+ T cells (per mL) 53 (19–157) 73 (24–242) 26 (13–32) 0.03
Total CD8+ T cells (per mL) 607 (422–1127) 741 (441–1153) 459 (409–631) 0.16
CD4:CD8 ratio 0.09 (0.02–0.20) 0.15 (0.03–0.28) 0.05 (0.02–0.09) 0.05
Naive CD4+ T cells (per mL) 2 (1–37) 5 (1–51) 1 (0–1) 0.006
Central memory CD4+ T cells (per mL) 19 (8–69) 29 (10–76) 14 (2–19) 0.06
Effector memory CD4+ T cells (per mL) 14 (4–40) 18 (4–42) 11 (8–18) 0.32
Naive CD8+ T cells (per mL) 97 (53–169) 112 (66–212) 53 (26–134) 0.10
Central memory CD8+ T cells (per mL) 97 (49–160) 98 (47–162) 83 (49–135) 0.89
Effector memory CD8+ T cells (per mL) 174 (96–492) 167 (97–516) 191 (78–423) 0.96
Effector CD8+ T cells (per mL) 174 (70–326) 265 (73–366) 123 (45–189) 0.13
Plasma HIV RNA (log10 copies/mL) 4.0 (2.5–4.9) 3.6 (2.4–4.9) 4.2 (3.1–4.8) 0.60
CSF HIV RNA (log10 copies/mL) 2.3 (2.2–4.0) 2.5 (2.0–4.4) 2.3 (2.3–2.3) 0.56
CSF JCV DNA (log10 copies/mL) 2.6 (2.0–3.2) 2.5 (1.3–3.1) 3.2 (2.5–4.8) 0.04
CSF JCV DNA (% .100 copies/mL) 85.7% [24/28] 80.9% [17/21] 100% [7/7] 0.55*
Note: Median values are shown, with interquartile range in parentheses. P-values are not adjusted for multiple comparisons. ART: antiretroviral therapy.C S F :
cerebrospinal fluid. T cells subsets are defined by the following antibody expression patterns: Naive subset, CD45RA+CD62L+; Central memory subset,
CD45RA2CD62L+; Effector memory subset, CD45RA2CD62L2; Effector subset, CD45RA+CD62L2.( mL=microliter, mL=millimeter).
doi:10.1371/journal.pone.0020967.t001
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In addition to enfuvirtide, 15 patients, including all 12 previously
untreated patients, received efavirenz, ritonavir-boosted lopinavir
and tenofovir/emtricitabine. The other 13 patients received other
combinations consisting of 2 or 3 reverse transcriptase inhibitors
(tenofovir 9, emtricitabine 7, abacavir 4, lamivudine 4, didanosine
3, efavirenz 2, zidovudine 1) plus 1 or 2 ritonavir-boosted protease
inhibitors (fosamprenavir 8, lopinavir 7, saquinavir 2, indinavir 2).
Percutaneous endoscopic gastrostomy tube for enteral feeding and
drugs administration was inserted in 7 patients with swallowing
disorders.
Survival
Seven patients died during the study period, all from PML, and
all before M4 including one with plasma HIV RNA below 40
copies/mL. The estimated one-year survival rate was 0.75 (95%
confidence interval, 0.61 to 0.93) (Figure 1). No significant
difference in terms of survival rate was observed between patients
enrolled in the main center and the other patients (0.80 vs. 0.63;
log-rank test, P=0.31). The survival rate did not differ
significantly between naı ¨ve and previously treated patients (0.67
vs. 0.81; log-rank test, P=0.44).
Changes in neurological and performance scores
A ss h o w ni nF i g u r e2( p a n e l sAa n dB ) ,t h ec l i n i c a lc o u r s ew a s
biphasic. Compared to baseline (Table 2), the standardized
neurological score worsened significantly at W6 and at M3
(Wilcoxon’s signed-rank test, respectively P=0.02 and P=0.008).
By contrast, it tended to improve at M6 as compared to M3
(P=0.10), and was no longer significantly different from baseline
(P=0.71). Similarly, compared to baseline, Karnofsky performance-
status deteriorated significantly at W6 (P=0.002) and M3 (P=0.02),
before improving at M6 (P=0.03) and M12 (P=0.001) relative to
M3. At M6 and M12, Karnofsky performance-status was no longer
significantly different from baseline (respectively, P=0.57, and
P=0.34). At M12, the 21 survivors had a median MRS of 3 (range,
1 to 5). Eight patients (38%) had no more than slight disability and
were independent for activities of daily living (MRS,3), 9 patients
(43%) weremoderatelydisabled (MRS=3),and 4 patients(19%) had
moderately severe to severe disability (MRS.3).
Viral kinetics
Treatment was rapidly and persistently effective on plasma HIV
RNA level (Figure 2 panel C): values were below 50 copies per
milliliter in 14% of patients (4/28) at baseline, 50% (13/26) at W6,
75% (18/24) at M3, 86% (18/21) at M6, 90% (19/21) at M9 and
81% (17/21) at M12. JCV DNA level in CSF also fell from
baseline to M6 (Figure 2 panel D): values were below 100 copies
per milliliter in 14% of patients (4/28) at baseline, 40% of patients
(10/25) at M3 (Fisher’s exact test, P=0.007) and 81% of patients
(17/21) at M6 (P,0.001).
Immunological changes
See Table 2. The CD4+ T-cell count increased significantly
from baseline to W6 (P=0.003), and at each subsequent time
point (Figure 3 panel A). At M12, the median CD4+ T-cell
increment was 105 per microliter (IQR, 18 to 127). In contrast, the
CD8+ T-cell count did not change significantly during follow-up
(Figure 3 panel B). As shown in Figure 3 (panel C), the CD4:CD8
ratio increased significantly at each time point vs. baseline, with
the exception of M12 compared to M6 (P=0.13).
The naive CD4+ T-cell count (Figure 3 panel D) increased
significantly from baseline to W6 (P=0.02) and from W6 to M3
(P=0.02), while it remained stable between M3 and M6 (P=0.50) and
increased markedly from M6 to M12 (P=0.005). Central memory and
effector memory CD4+ T-cell numbers increased significantly from
baseline to W6 (respectively, P=0.01 and P=0.005), with no
significant variations thereafter (Figure 3 panels E and F).
Naive CD8+ T-cell numbers increased only from W6 to M3
(P=0.05) (not shown). No significant change was observed in the
numbers of central memory, effector memory or effector CD8+
T-cells.
Significant restoration of anti-JCV CD4+ T-cell proliferation to
purified JCV was observed, starting at M3 (Figure 4 panel A). The
Figure 1. Survival of PML patients on five-drug antiretroviral treatment. Kaplan-Meier estimates and 95% confidence interval of the survival
rate during five-drug antiretroviral therapy after PML diagnosis. Baseline is the date of the first dose of enfuvirtide. Follow-up is censored at 12
months. The one-year cumulative probability of survival was 0.75 (95% CI, 0.61–0.93). Seven patients died, all before 4 months.
doi:10.1371/journal.pone.0020967.g001
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to 29% at M3 (McNemar’s test, P=0.03) and to 43% at M6 and
M12 (P=0.008).
Using an ex vivo interferon gamma Elispot assay and overlapping
peptide pools covering the entire VP1 protein to test effector T-cell
responses including mainly CD8+ T-cell responses, we found no
significant changes in the percentage of patients responding to at
least one peptide pool between baseline (19%) and M12 (33%,
P=0.51) or any other time during the follow-up (Figure 4 panel
B). We then analyzed the range of effector T-cell responses during
follow-up. At baseline and W6, four patients responded to a single
peptide pool (mean of responding pools=0.19 in the 21 survivors).
At M3, the mean number of responding pools was 2.20 and 0.52
in responders and in all survivors, respectively. The respective
mean numbers were 1.43 and 0.48 at M6 vs. 3.86 and 1.29 at
M12. Among the 21 survivors, paired analysis showed a trend
towards a larger number of responding peptide pools at M12 as
compared to baseline (Wilcoxon’s signed-rank test, P=0.10)
(Figure 4 panel C). Interestingly, in a given patient, anti-JCV
effector T-cell responses were variable during follow-up (Figure 4
panel C).
Factors associated with survival
See Table 1. Patients who died had lower baseline peripheral
CD4+ T-cell counts than survivors and tended to have lower
CD4:CD8 ratios. The naive CD4+ T-cell count at baseline was
Figure 2.Time course of clinical and virological parameters. Biphasic course of a normalized neurological score from baseline to M6 (panel A)
and of the Karnofsky performance score from baseline to M12 (panel B). Early and sustained plasma HIV RNA response from baseline to M12 on early
five-drug antiretroviral therapy (panel C). Significant reduction in JCV DNA in CSF at M6 (panel D). Whiskers represent medians and interquartiles.
Wilcoxon’s signed-rank test : * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0020967.g002
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memory CD4+ T-cell numbers tended to be lower at baseline in
patients who died than in survivors. Likewise, patients who died
tended to have lower baseline naive CD8+ T-cell counts than
survivors and lower effector CD8+ T-cell counts. Moreover,
baseline CSF JCV DNA levels measured in 27 patients were
significantly higher in patients who died than in survivors.
The time between clinical onset and study entry, the baseline
neurological examination score, Karnofsky performance-status
and HIV RNA levels in plasma and CSF were not significantly
different between patients who died and those who survived.
Furthermore, activity level of antiretroviral drugs into the CNS,
evaluated by the 2010-revised CNS Penetration Effectiveness
Score [24], did not differ significantly between survivors and non
survivors (Mann-Whitney test, P=0.914).
In summary, higher counts of total and naive CD4+ T-cells at
baseline, along with lower JCV DNA levels, were associated with
better survival. Among baseline immunological markers, a higher
CD4:CD8 ratio, a higher central memory CD4+ T-cell count and
a higher naive CD8+ T-cell count tended to be associated with
better survival.
JCV-specific CD4+ T-cell proliferative responses were detected
at least once during follow-up in 52% (11/21) of survivors and in
none of the 7 patients who died (Fisher’s exact test, p=0.023),
while specific effector T-cell responses were found in 76% (16/21)
of survivors and in 29% (2/7) of patients who died (P=0.06).
Moreover no correlation was observed between JCV viral load
in CSF and JCV-specific T-cell responses both at baseline and
during follow-up (M3 and M6). Finally no relationship has been
found between neurological outcome (evaluated by MRS) and
JCV-specific T-cell responses at M12 as well as JCV viral load
during follow-up.
Safety
A possible immune restoration inflammatory syndrome (IRIS)
occurred in a treatment-naive patient with a baseline CD4+ T-cell
count of 167 per microliter, whose neurological status markedly
deteriorated (right hemiplegia, aphasia, double hemianopia and
dysphagia) during the first 6 weeks of ART. At W6, the CD4+
T-cell count was 214 per microliter and cerebral MRI showed
extension of demyelination to the white matter of both
hemispheres, including the corpus callosum. A mass effect on
the left ventricle and perilesional contrast enhancement were also
observed. The patient improved rapidly on steroid therapy. Of
note, this patient had no detectable specific CD4+ T-cell responses
during the study period, and a positive anti-JCV effector T-cell
response was observed only at M12.
Six serious adverse events occurred in 6 different patients,
consisting of one case each of bicytopenia, bilateral pulmonary
embolism, partial epilepsy, acute respiratory distress syndrome,
biochemical deterioration of hepatitis C, and hysterectomy for
severe cervical dysplasia. With the exception of bicytopenia, these
serious adverse events were assessed as not directly related to the
antiretroviral therapy. All serious events resolved, except in the
patient with severe hepatitis C, whose liver status continued to
deteriorate despite interruption of ART and who died at week 6. All
other patients were still alive at the end of the study. Enfuvirtide was
never withdrawn. Urolithiasis occurred in a patient on indinavir,
which was replaced by atazanavir. No significant variations in
creatinine clearance, calcemia or phosphatemia occurred in the 24
patients receiving tenofovir.
Discussion
In this study the one-year cumulative probability of survival
after PML diagnosis was 75% (95% confidence interval, 0.61 to
0.93), a rate higher than previously reported in HIV-infected
patients placed on conventional triple-drug ART after PML
diagnosis (39% to 56%) [10–15,19,25]. This suggests that a five-
drug antiretroviral regimen given early after PML diagnosis may
improve survival. With a five-drug combination, none of our
patients died after four months. However, this treatment remains
insufficient for patients with very rapidly progressive disease. As a
result, this study also showed a 4-month survival rate of 75%. In
previous reports concerning standard cART [13,20], most PML-
related deaths occurred during the first months with a median time
of 1.6 to 4.3 months following PML diagnosis. In the Danish HIV
Cohort Study, 35 of the 47 patients, diagnosed with PML between
1995 and 2006, died during the study period, including 18 (38.3%)
whose death occurred within 4 months after the onset of PML [3].
In a more recent study of patients diagnosed with PML between
2002 and 2006, the probability of survival was 61% (95% CI, 48 to
Table 2. Changes from baseline characteristics.
Variables Week 6 Month 3 Month 6 Month 12
Standardized Neurological Score 20.2 (21.0–0.1) 20.3 (21.2–0.1) 0.0 (203–0.4)
Karnofsky Performance-Status 210 (220–0) 210 (230–5) 0 (220–10) 0 (210–10)
Total CD4+ T cells 24 (0–58) 35 (7–86) 66 (45–117) 105 (18–127)
Total CD8+ T cells 80 (242–336) 45 (2111–365) 69 (2130–328) 111 (270–327)
Naive CD4+ T cells) 2( 20.2–5) 2 (0–9) 12 (3–34) 29 (24–54)
Central memory CD4+ T cells 7 (1–34) 11 (0.2–40) 22 (5–41) 49 (11–61)
Effector memory CD4+ T cells 7( 20.1–21) 8 (2–24) 12 (5–24) 10 (20.1–21)
Naive CD8+ T cells 21 (29–37) 27 (226–60) 26 (10–85) 69 (17–135)
Central memory CD8+ T cells 25( 219–31) 216 (238–11) 28( 246–28) 8 (231–72)
Effector memory CD8+ T cells 34 (225–150) 20.2 (285–126) 3 (272–36) 14 (258–169)
Effector CD8+ T cells 7( 249–59) 12 (274–79) 18 (229–116) 11 (235–125)
Note: Median change relative to baseline is shown, with interquartile range in parentheses. T cells subsets are defined by the following antibody expression patterns:
Naive subset, CD45RA+CD62L+; Central memory subset, CD45RA2CD62L+; Effector memory subset, CD45RA2CD62L2; Effector subset, CD45RA+CD62L2. Values of T
cells (total and subsets) are cells per microliter.
doi:10.1371/journal.pone.0020967.t002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20967Figure 3. Time course of CD4+ and CD8+ T cell populations from baseline to month 12. Compared to baseline, significant increases were
observed at W6 and at each subsequent time point in: the CD4+ T cell count (panel A); the CD4:CD8 ratio (panel C); naive CD4+ T cells (panel D); central
memory CD4+ T cells (panel E); and effector memory CD4+ T cells (panel F). No significant variation in the CD8+ T cell count (panel B) was noted during
follow-up. (naive=CD45RA+CD62L+, central memory=CD45RA2CD62L+), effector memory=CD45RA2CD62L2). Whiskers represent medians and
interquartiles. Black lines represent survivors and grey lines patients who died. Wilcoxon’s signed-rank test : * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0020967.g003
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(95% CI, 25 to 51) at 12 months [25].
There are few longitudinal studies of the clinical course of PML
during cART. In a previous paper [12], we showed no significant
change in neurological assessment based on the EDSS score
between the last time point (median 539 days) and cART
initiation. On the MRS, 38% of the survivors in our study had,
at most, slight disability, as compared to 31% of 42 historical
control patients [9]. By contrast, the odds of having moderately
severe to severe disability 12 months after PML diagnosis were
lower (19%) than in a multicohort study of 370 patients with PML
placed on conventional cART (39%) [15].
The low incidence of HIV-related PML led us to choose an
open-label non comparative study design. To demonstrate in a
randomized controlled study that a one-year survival rate of 70%,
was significantly higher than 45% which was the average of the
survival rate observed in previous published studies [11–13,15,19],
it would have been necessary to enroll 128 patients. These studies
included patients treated with standard triple-drug antiretroviral
combinations mainly between January 1996 and February 2004.
Our patients were similar at PML diagnosis to the patients
described in these five historical series and in three more recent
reports [3,14,25], with respect to proportion of ARV-naı ¨ve
patients, CD4 T-cell count, plasma viral load (for more
information, see Table S2).
Use of triple-drug cART in patients with AIDS-related PML
can cause IRIS [19,25–27]. The use of five-drug cART could
potentially augment the frequency and severity of PML-IRIS. In
our study, one possible case of IRIS was observed, 6 weeks after
initiation of the study treatment in a previously ART-naive
patient. The diagnosis of IRIS was based on clinical deterioration
and on MRI evidence of inflammatory modifications of PML
lesions. The clinical status of PML patients frequently keeps on
deteriorating during the first weeks of ART, possibly owing to the
delay in anti-JCV immune recovery (see Fig. 2). In our patient,
perilesional contrast enhancement and a mass effect on the left
ventricle, observed on MRI, supported the diagnosis of IRIS.
Steroids were rapidly effective, as in a retrospective study of a large
cohort of patients with IRIS-associated PML [26]. In our study,
the upper limit of the 95% confidence interval of IRIS occurrence
(1/28) was 18%. In comparison, PML-associated IRIS have been
reported in 18% to 23% of patients in the setting of standard
triple-drug ART [19,25,26]. Thus, five-drug combination does not
seem to increase the risk of PML-associated IRIS.
In this study, survival of PML patients was associated with a
high rate of JCV clearance from CSF, as previously reported
[9,10,12,28]. Combined antiretroviral therapy may act on
intracerebral JCV replication by reducing HIV replication and
inflammation in the brain. A transactivating effect of HIV Tat
protein on JCV promoters has also been reported [29]. Blood-
brain barrier modifications due to HIV infection may favor the
entry of JCV-harboring B cells, while local cytokine production
may enhance JCV replication [1]. However, the main mechanism
by which ART acts on JCV replication is likely to be the recovery
of specific anti-JCV responses. Indeed, we observed significant
recovery of specific CD4+ T-cell proliferative responses from M3
to M12, and this was associated with better survival, in line with
the result of a cross-sectional study [8]. Among memory CD4+
T-cells, proliferation is mainly the hallmark of central memory
cells, which are also associated with CD4 help to memory CD8+
T-cells [7,30,31]. Several lines of evidence show the critical role of
CD4 help for the maintenance of effective secondary cytotoxic
CD8+ T-cell responses [7,32,33]. Of interest, at baseline, the
number of circulating naive CD4+ T-cells and, to a lesser extent,
the number of central memory CD4+ T-cells, were higher in PML
patients who survived. The presence of a larger residual pool of
central memory and naive CD4+ T-cells in subsequent survivors
may accelerate the return of an effective JCV-specific memory
CD4+ T-cell response during five-drug cART. This could involve
some functional recovery of JCV-specific memory cells, and
improved generation of memory CD4+ T-cells from the residual
naive pool following effective inhibition of HIV replication. The
existence of only small residual pool of naive CD4+ T-cells might
therefore be a limiting factor in the immune control of
intracerebral JCV replication, given the slow expansion of these
cells during effective cART (Fig. 3D).
Better outcome of PML has been linked to the detection of anti-
JCV peripheral blood CD8+ CTL after peptide stimulation in vitro
for 10 to 14 days [6,34]. Here, we used an ex vivo procedure,
without in vitro amplification, to assess circulating IFN-gamma-
producing anti-JCV T-cell effectors including mainly CD8+
effectors. Survival was not associated with the detection of anti-
JCV T-cell effectors at baseline, but most JCV-specific T-cell
effectors might be located in brain tissue, where JCV replication
occurs predominantly during active PML. This, in addition to the
inconstancy of detection of anti-JCV T-cell effectors in a given
patient during follow-up, would mean that the blood compartment
does not accurately reflect anti-JCV T-cell responsiveness. This is
consistent with recent studies based on the use of specific
tetramers, that showed a very low frequency of anti-JCV specific
CD8+ T-cells in peripheral blood, relative to infections by less
anatomically restricted viruses such as HIV, EBV and CMV [35].
Moreover, while a drastic fall in CSF JCV DNA level occurred in
most of our patients at M6, the percentage of patients whose
peripheral cells responded in the Elispot assay did not increase
during follow-up. However, at M12, a trend towards a broader
repertoire of circulating anti-JCV T-cell responses was observed.
This emergence of additional anti-JCV specificities in blood could
result from several mechanisms, including redistribution of CD8+
T-cells previously trapped in brain tissue, generation of new anti-
JCV memory CD8+ T-cells, and improved function of pre-existing
memory cells. The last two mechanisms are dependent on help
from anti-JCV CD4+ T-cells, which expanded during ART.
By accelerating HIV decay, five-drug antiretroviral combina-
tion may lead to more rapid anti-JCV immune reconstitution.
However, 25% of patients still die within 4 months of treatment
initiation. Moreover, only 38% of survivors recovered adequate
autonomy for activities of daily living. The size of the residual
naive and central memory CD4+ T-cell pools may influence the
time required for effective CD8-helping CD4+ T-cell responses to
recover during cART. These pools could therefore represent
targets for immunotherapy based on cytokines such as IL-7 [36].
In conclusion, our results support the use of five-drug cART
early during the course of PML, for both antiretroviral-naive and
-experienced patients.
Figure 4. JCV-specific T-cell responses during follow-up. Panel A: Analysis of anti-JCV CD4+ T cell responses. Panel B: Analysis of ex-vivo anti-
JCV CD8+ T-cell responses. A patient was considered to be a responder if he or she had a positive response to at least one JCV VP1 overlapping
peptide pool among the 14 pools tested. Panel C shows the percentage of responding pools among the 14 pools tested in each survivor during
follow-up. Five of the 21 survivors who had no responses at any time are not represented.
doi:10.1371/journal.pone.0020967.g004
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have been modified to take into account bilateral damage. PML
Score ranges from 0 to 60 points. This score is not yet validated at
present.
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